For laboratory research use only — not for human or veterinary use. Not evaluated by the U.S. FDA.
Metabolic Peptide
Eloralintide
A selective amylin receptor agonist investigated in clinical research for metabolic regulation and body composition.
Quantity
$278.99
Bundle & save
Delivery
Order by 3:00 PM ET for same-day dispatch
Cutoff 3:00 PM ET · same-day dispatch
Estimated arrival in 2–3 business days
Overnight shipping available
Free shipment protection included
Eloralintide
1 × 13mg · $278.99
99% purity, QC passed
HPLC + mass-spec verified
Shipment protection
Free on every order
Free shipping over $150
Same-day dispatch before 3PM ET
Certificate of Analysis
Third-party tested · Independent analytical lab
13mg
99.54%latest
| Tested | Measured | Purity |
|---|---|---|
| Jul 2026 | 13.99mg | 99.54% |
| Jun 2026 | 13.33mg | 99.82% |
| May 2026 | 13.78mg | 99.52% |
Frequently researched together
Commonly studied alongside Eloralintide.
Compound information
Technical specifications
Molecular profile
| Type | Selective amylin receptor agonist peptide |
| CAS number | 2883634-40-8 |
| Molecular weight | 4526 g/mol |
| Formula | C201H319N49O65S2 |
Storage & stability
- ❄️
Lyophilized (powder)
-20°C · stable 2+ years
- ❄️
Reconstituted
2–8°C · use within 30 days
Sources & references
Peer-reviewed literature, for research context
- Lancet (London, England)
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
2025·DOI: 10.1016/S0140-6736(25)02155-5·PMID: 41207310Billings LK, Hsia S, Bays H, Tidemann-Miller B, O'Hagan J, Tham LS
View source - Molecular metabolism
Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept
2025·DOI: 10.1016/j.molmet.2025.102271·PMID: 41109426Briere DA, Qu H, Lansu K, He MM, Moyers JS, Coskun T
View source - Diabetes, obesity & metabolism
Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept
2026·DOI: 10.1111/dom.70439·PMID: 41559929Bhattachar S, Tham LS, Tidemann-Miller B, Ibriga H, Qu H, Briere DA
View source
Important research notice
Not for human consumption. This product is sold exclusively for laboratory and in vitro research. It is not intended to diagnose, treat, cure, or prevent any disease.
Any research findings referenced on this page are drawn from published, peer-reviewed literature and are provided for educational context only. They are not product claims and should not be read as medical advice.
By purchasing, you confirm you are a qualified researcher and will handle this material in accordance with all applicable laws and institutional guidelines.